查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肌肉萎缩疾病的全球市场：成长、未来前景、竞争分析，2024-2032年
市场调查报告书
商品编码
1552375

肌肉萎缩疾病的全球市场：成长、未来前景、竞争分析，2024-2032年

Muscle Wasting Disorders Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
出版日期: | 出版商: Acute Market Reports | 英文 171 Pages | 商品交期: 最快1-2个工作天内

价格

肌肉消耗性疾病是以肌肉量和力量显着下降为特征的疾病，近年来受到越来越多的医学关注。这些疾病包括多种疾病，从与年龄相关的肌肉减少症到肌肉营养不良等神经肌肉疾病。预计2024年至2032年，肌肉萎缩疾病的市场规模将以 15.5%的年复合成长率成长。

促进因素：人口老化和相关肌肉减少症的增加

肌肉消耗疾病市场的主要驱动力之一是世界人口老化的快速增加。随着婴儿潮世代进入老年人口，肌少症（一种与老化密切相关的肌肉无力疾病）的盛行率迅速增加。根据联合国世界人口老化报告，预计到2050年，60岁及以上的人口数量将增加一倍。这种人口结构的变化导致肌少症病例增加。再加上肌肉无力会倍增残疾、跌倒、骨折和全因死亡率的风险，医疗保健产业正致力于对抗这种疾病。从荷尔蒙替代疗法到力量训练方案等多种治疗策略引起人们的关注，这表明该市场的潜力不断成长。

机会：神经肌肉疾病基因治疗的进展

基因治疗领域在解决某些肌肉萎缩疾病的根本原因方面已经显示出有希望的结果，特别是肌肉萎缩症等遗传性疾病。最近的案例研究描述了基因疗法如何成功引进或修饰特定基因，改善肌肉功能并减缓疾病进展。例如，New England Journal of Medicine上发表的一篇论文详细介绍了一项基因治疗试验，该试验显示患有某些类型肌肉营养不良症的儿童的运动功能得到改善。随着基因研究的进步和导致这些疾病的突变的发现，开发标靶疗法的机会将扩大并有可能改变治疗格局。

抑制因素：治疗费用高、获取机会有限

治疗和管理方面的进步是有希望的，但成本很高。尖端疗法，尤其是基因疗法，成本高。其中许多治疗不在保险范围内，给患者带来了沉重的经济负担。此外，由于专门治疗中心数量有限，获得治疗的机会有限，主要是在低收入和中等收入国家。Journal of Clinical Medicine上发表的一项研究强调了神经肌肉疾病治疗的可用性存在显着的地区差异，并确定了实现全球采用的市场挑战。

挑战：临床影像的多样性和诊断难度

肌肉萎缩疾病的临床症状差异很大，早期诊断往往很困难。鑑于及时介入对控制病情进展的重要性，这种诊断延迟可能会危及患者的治疗结果。肌肉活检是诊断某些肌肉萎缩疾病的黄金标准之一，但它是侵入性的，并不总是得出结论性的结果。 Muscle & Nerve杂誌上发表的一篇论文描述了一个案例，其中肌肉病理切片检查产生非特异性结果，需要进一步的诊断程序。这种差异不仅延长了诊断所需的时间，而且还放大了与这些疾病相关的情绪和经济痛苦。

依类型细分市场

就收入而言，肌肉萎缩症将推动2023年的细分市场。这是由于其普遍存在，尤其是在儿科人群中，以及与其管理相关的高昂成本，包括物理治疗、手术干预和药物治疗。对肌肉营养不良症，特别是杜氏肌肉营养不良症（DMD）的研究重点，为基因治疗和外显子跳跃药物等治疗创新铺平了道路，进一步推动了收入极限。相较之下，肌肉萎缩通常是由神经肌肉疾病和病症（如 ALS、脊髓性肌肉萎缩和神经损伤）引起的，并且具有最高的年复合成长率（CAGR）。意识的提高、早期诊断干预以及针对脊髓性肌肉萎缩症（SMA）等疾病的新兴治疗管道推动这一成长轨迹，预计这一趋势将在2024年至2032年持续下去。

最终用户的市场区隔

2023年，医院成为肌肉萎缩疾病市场的主要收入来源。这项优点源自于在同一屋檐下提供全面的护理，包括诊断、治疗、手术和復健。多学科方法在这些疾病的管理中变得非常重要，有利于医院的全人照护模式。然而，预计2024年至2032年康復中心的年复合成长率最高。随着重点转向改善生活品质、维持运动功能和减缓疾病进展，復健治疗在肌肉萎缩疾病管理中的作用变得非常重要。专门从事物理治疗、职业治疗、语言治疗等的中心变得越来越重要。专门从事利基治疗领域和家庭护理等其他领域的专科诊所也发挥着重要作用，患者寻求个人化和专门的治疗，或更喜欢在自己舒适的家中接受治疗。

区域市场区隔

北美凭藉其先进的医疗基础设施、研究计划和患者意识，在2023年占据了最大的销售占有率。 FDA 批准治疗 DMD 和 SMA 等疾病的药物以及大型製药公司的存在增强了该地区的主导地位。然而，预计2024年至2032年亚太地区的年复合成长率最高。医疗保健成本上升、对肌肉消耗疾病的认识提高以及诊断基础设施的改善等因素促成了这一预计的成长。此外，快速成长的人口和未开发市场的存在为该地区的市场扩张提供了有利的机会。

竞争趋势

肌肉萎缩疾病市场的特征是竞争激烈，竞争对手包括 Biogen, Inc.、F. Hoffmann-La Roche Ltd、Novartis AG、Ionis Pharmaceuticals, Inc.、Sarepta Therapeutics, Inc.、Nippon Shinyaku Co., Ltd（NS Pharma, Inc.）、PTC Therapeutics, Inc. 和Teva Pharmaceutical Industries Ltd. 在2023年处于领先地位。这些公司主要致力于合併、收购、研究合作关係和积极的研发投资等策略，以维持其市场地位。例如，Roche收购 Spark Therapeutics 巩固了其在基因治疗领域的立足点，特别是针对肌肉萎缩疾病。此外，致力于患者支持计划以增加获得药物的机会，即使成本高昂，也已成为一项值得注意的策略。从2024年到2032年，这些参与者预计将继续进行技术创新、联合研究和策略联盟来推动市场发展。

本报告回答的主要问题

影响肌肉消耗疾病市场成长的关键微观和宏观环境因素有哪些？

现在和预测期内，就产品领域和地区而言，主要投资领域为何？

2032年之前的预估与市场预测

哪个细分市场在预测期间内年复合成长率最快？

哪个细分市场拥有较大的市场占有率，为什么？

低收入和中等收入国家是否投资肌肉萎缩疾病市场？

肌肉消耗疾病市场最大的区域市场是哪一个？

亚太地区、拉丁美洲和中东、非洲等新兴市场的市场趋势和动态是什么？

推动肌肉消耗疾病市场成长的主要趋势是什么？

主要竞争对手是什么？ 他们提高在全球肌肉消耗疾病市场占有率的关键策略是什么？

目录

第1章 前言

  • 报告内容
    • 报告的目的
    • 目标受众
    • 主要提供
  • 市场区隔
  • 调查方法
    • 第一阶段 - 二次调查
    • 第二阶段 - 初步调查
    • 第三阶段 - 专家评审
    • 先决条件
    • 采用的方法

第2章 执行摘要

第3章 肌肉消耗疾病市场：竞争分析

  • 主要供应商的市场定位
  • 供应商采取的策略
  • 主要产业战略
  • 层级分析：2023年与2032年

第4章 肌肉​​消耗性疾病市场：宏观分析与市场动态

  • 简介
  • 2022-2032年全球肌肉消耗性疾病市场价值
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 主要挑战
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • See-Saw分析
  • 波特的五力模型
    • 供应商公司的力量
    • 买家的购买力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的对抗关係
  • PESTEL 分析
    • 政治局势
    • 经济情势
    • 技术状况
    • 法律状况
    • 社会状况

第5章 肌肉消耗疾病市场：依类型划分，2022-2032

  • 市场概览
  • 成长/利润分析：2023年与2032年
  • 市场区隔
    • 肌肉营养不良症
    • 肌肉萎缩

第6章 肌肉消耗疾病市场：依治疗类型划分，2022-2032年

  • 市场概览
  • 成长/利润分析：2023年与2032年
  • 市场区隔
    • 药物治疗
    • 物理治疗
    • 营养治疗
    • 手术治疗
    • 基因治疗
    • 其他

第7章 肌肉消耗性疾病市场：依最终使用者，2022-2032年

  • 市场概览
  • 成长/利润分析：2023年与2032年
  • 市场区隔
    • 医院
    • 復健中心
    • 专科诊所
    • 其他

第8章 北美肌肉萎缩疾病市场，2022-2032

  • 市场概览
  • 肌肉消耗性疾病市场：依类型，2022-2032年
  • 肌肉消耗性疾病市场：依治疗类型，2022-2032年
  • 肌肉消耗性疾病市场：依最终使用者，2022-2032年
  • 肌肉消耗性疾病市场：依地区，2022-2032年
    • 北美
      • 美国
      • 加拿大
      • 北美其他地区

第9章 英国/欧盟肌肉萎缩疾病市场，2022-2032年

  • 市场概览
  • 肌肉消耗性疾病市场：依类型，2022-2032年
  • 肌肉消耗性疾病市场：依治疗类型，2022-2032年
  • 肌肉消耗性疾病市场：依最终使用者，2022-2032年
  • 肌肉消耗性疾病市场：依地区，2022-2032年
    • 英国/欧盟
      • 英国
      • 德国
      • 西班牙
      • 义大利
      • 法国
      • 欧洲其他地区

第10章 亚太地区肌肉萎缩疾病市场，2022-2032

  • 市场概览
  • 肌肉消耗性疾病市场：依类型，2022-2032年
  • 肌肉消耗性疾病市场：依治疗类型，2022-2032年
  • 肌肉消耗性疾病市场：依最终使用者，2022-2032年
  • 肌肉消耗性疾病市场：依地区，2022-2032年
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳洲
      • 韩国
      • 亚太地区其他地区

第11章 拉丁美洲肌肉萎缩疾病市场，2022-2032

  • 市场概览
  • 肌肉消耗性疾病市场：依类型，2022-2032年
  • 肌肉消耗性疾病市场：依治疗类型，2022-2032年
  • 肌肉消耗性疾病市场：依最终使用者，2022-2032年
  • 肌肉消耗性疾病市场：依地区，2022-2032年
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第12章 中东与非洲肌肉萎缩疾病市场，2022-2032

  • 市场概览
  • 肌肉消耗性疾病市场：依类型，2022-2032年
  • 肌肉消耗性疾病市场：依治疗类型，2022-2032年
  • 肌肉消耗性疾病市场：依最终使用者，2022-2032年
  • 肌肉消耗性疾病市场：依地区，2022-2032年
    • 中东、非洲
      • GCC
      • 非洲
      • 其他中东、非洲

第13章 公司简介

  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Nippon Shinyaku Co. Ltd.（NS Pharma Inc.）
  • PTC Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • 其他主要公司
Product Code: 374-07-24

Muscle wasting disorders, characterized by the significant reduction of muscle mass and strength, have been the subject of increased medical attention over recent years. These conditions encompass a variety of diseases ranging from sarcopenia, typically related to aging, to neuromuscular disorders like muscular dystrophy. The muscle wasting disorders market is estimated to grow at a CAGR of 15.5% from 2024 to 2032.

Driver: Increasing Aging Population and Associated Sarcopenia

One of the primary drivers for the muscle wasting disorders market is the exponential rise in the global aging population. As the baby boomer generation enters the senior age bracket, the prevalence of sarcopenia - a muscle wasting condition closely associated with aging - has surged. According to the United Nations' report on World Population Aging, the number of individuals aged 60 years or older is expected to double by 2050. This demographic shift has led to an uptick in cases of sarcopenia. Compounded by the fact that muscle wasting exponentially increases the risk of physical disabilities, falls, fractures, and overall mortality, the healthcare industry's focus on combating this disorder has intensified. Treatment strategies ranging from hormone replacement therapies to strength training regimens have garnered attention, signifying the market's expansive potential.

Opportunity: Advancements in Genetic Therapies for Neuromuscular Disorders

The realm of genetic therapies has showcased promising results in addressing the root causes of certain muscle wasting disorders, especially those of a hereditary nature like muscular dystrophy. Recent case studies highlight instances where gene therapies have been successful in introducing or correcting specific genes, leading to improved muscle function and reduced disease progression. For instance, a publication in the New England Journal of Medicine detailed a gene therapy trial that demonstrated improved motor functions in children with a specific type of muscular dystrophy. As genetic research continues to unveil the underlying mutations causing these disorders, the opportunity to develop targeted therapies expands, potentially revolutionizing the treatment landscape.

Restraint: High Treatment Costs and Limited Accessibility

While advancements in treatment and management are promising, they come at a steep price. The costs associated with cutting-edge treatments, especially genetic therapies, are exorbitant. Many of these treatments are not universally covered by insurance, placing a significant financial burden on patients. Furthermore, the limited availability of specialized treatment centers, primarily in low-to-middle-income countries, restricts access to care. A study in the Journal of Clinical Medicine emphasized the significant disparities in the availability of neuromuscular disorder treatments across different regions, elucidating the market's challenges in achieving global reach.

Challenge: Variability in Clinical Presentation and Diagnostic Difficulties

Muscle wasting disorders present with a wide variability in clinical symptoms, often making early diagnosis challenging. Given that timely intervention is crucial to manage progression, this diagnostic delay can lead to compromised patient outcomes. Muscle biopsies, one of the gold standards in diagnosing certain muscle-wasting disorders, are invasive and might not always provide conclusive results. An article in the Muscle & Nerve journal highlighted instances where muscle biopsies yielded non-specific results, necessitating further diagnostic procedures. This variability not only prolongs the diagnostic journey but also amplifies the emotional and financial distress associated with these disorders.

Market Segmentation by Type

In terms of revenue generation, muscular dystrophy led the market segment in 2023. This can be attributed to its prevalence, especially in the pediatric population, and the high costs associated with its management, which include physiotherapy, surgical interventions, and medications. The research focus on dystrophic conditions, especially Duchenne Muscular Dystrophy (DMD), has paved the way for innovations in treatments like gene therapies and exon skipping drugs, further pushing the revenue envelope. In contrast, muscular atrophy, often a consequence of neuromuscular diseases or conditions like ALS, spinal muscular atrophy, or nerve injuries, demonstrated the highest Compound Annual Growth Rate (CAGR). The rising awareness, early diagnostic interventions, and burgeoning therapeutic pipelines for conditions like Spinal Muscular Atrophy (SMA) contribute to this growth trajectory, expected to continue from 2024 to 2032.

Market Segmentation by End-User

In 2023, hospitals emerged as the principal revenue contributor for the muscle wasting disorders market. This dominance was attributed to the comprehensive care offered, including diagnostics, therapeutics, surgeries, and rehabilitation, all under one roof. As multidisciplinary approaches became essential for managing these disorders, hospitals' holistic care model was preferred. However, from 2024 to 2032, it's expected that rehab centers will showcase the highest CAGR. As the emphasis shifts towards improving quality of life, maintaining mobility, and delaying disease progression, the role of rehabilitative therapies in muscle wasting disorders management becomes paramount. These centers, specializing in physiotherapy, occupational therapy, and speech therapy, among others, are becoming increasingly pivotal. Specialty clinics, focusing on niche therapeutic areas, and other segments like home care also play crucial roles, with patients seeking personalized, specialized care or preferring treatments within the comfort of their homes.

Market Segmentation by Region

North America, with its advanced healthcare infrastructure, research initiatives, and patient awareness, held the largest revenue share in 2023. The FDA's approval of drugs for conditions like DMD and SMA, coupled with the presence of major pharmaceutical players, propelled the region's dominance. However, the Asia-Pacific region is anticipated to exhibit the highest CAGR from 2024 to 2032. Factors like increasing healthcare expenditure, rising awareness of muscle wasting disorders, and improving diagnostic infrastructure contribute to this forecasted growth. Moreover, the burgeoning population and the presence of untapped markets present lucrative opportunities for market expansion in this region.

Competitive Trends

The muscle wasting disorders market is characterized by intense competition, with major players like Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd. leading the charge in 2023. These companies primarily focused on strategies like mergers, acquisitions, research collaborations, and aggressive R&D investments to maintain their market positions. For instance, Roche's acquisition of Spark Therapeutics accentuated its foothold in the gene therapy arena, especially concerning muscle wasting disorders. Additionally, the emphasis on patient assistance programs, ensuring drug accessibility even with high costs, became a notable strategy. Moving forward, from 2024 to 2032, it's expected that these players will continue their innovations, collaborations, and strategic alliances, driving the market forward.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Muscle Wasting Disorders market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Muscle Wasting Disorders market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Type

    • Muscular Dystrophy
  • Duchenne Muscular Dystrophy (DMD)
  • Becker Muscular Dystrophy (BMD)
  • Myotonic Muscular Dystrophy
  • Congenital Muscular Dystrophy
  • Limb-Girdle Muscular Dystrophy
  • Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
    • Muscular Atrophy
  • Physiologic Atrophy
  • Pathologic Atrophy
  • Neurogenic Atrophy

Treatment Type

    • Medications
    • Physical Therapy
  • Ultrasound Therapy
  • Electric Simulation
    • Nutritional Therapy
    • Surgery
    • Gene Therapy
    • Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

End-User

    • Hospitals
    • Rehab Centers
    • Specialty Clinics
    • Others (Homecare, etc.)

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Muscle Wasting Disorders market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Muscle Wasting Disorders market?

Which is the largest regional market for Muscle Wasting Disorders market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Muscle Wasting Disorders market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Muscle Wasting Disorders market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Muscle Wasting Disorders Market
  • 2.2. Global Muscle Wasting Disorders Market, By Type, 2023 (US$ Million)
  • 2.3. Global Muscle Wasting Disorders Market, By Treatment Type, 2023 (US$ Million)
  • 2.4. Global Muscle Wasting Disorders Market, By End-User, 2023 (US$ Million)
  • 2.5. Global Muscle Wasting Disorders Market, By Geography, 2023 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2023

3. Muscle Wasting Disorders Market: Competitive Analysis

  • 3.1. Market Positioning of Key Muscle Wasting Disorders Market Vendors
  • 3.2. Strategies Adopted by Muscle Wasting Disorders Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Muscle Wasting Disorders Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Muscle Wasting Disorders Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Muscular Dystrophy
      • 5.3.1.1. Duchenne Muscular Dystrophy (DMD)
      • 5.3.1.2. Becker Muscular Dystrophy (BMD)
      • 5.3.1.3. Myotonic Muscular Dystrophy
      • 5.3.1.4. Congenital Muscular Dystrophy
      • 5.3.1.5. Limb-Girdle Muscular Dystrophy
      • 5.3.1.6. Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
    • 5.3.2. Muscular Atrophy
      • 5.3.2.1. Physiologic Atrophy
      • 5.3.2.2. Pathologic Atrophy
      • 5.3.2.3. Neurogenic Atrophy

6. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. Medications
    • 6.3.2. Physical Therapy
      • 6.3.2.1. Ultrasound Therapy
      • 6.3.2.2. Electric Simulation
    • 6.3.3. Nutritional Therapy
    • 6.3.4. Surgery
    • 6.3.5. Gene Therapy
    • 6.3.6. Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

7. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals
    • 7.3.2. Rehab Centers
    • 7.3.3. Specialty Clinics
    • 7.3.4. Others (Homecare, etc.)

8. North America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 8.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 8.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 8.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 8.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 8.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 8.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 8.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 8.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 8.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

9. UK and European Union Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 9.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 9.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 9.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 9.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 9.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

10. Asia Pacific Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 10.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 10.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 10.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 10.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 10.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

11. Latin America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 11.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 11.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 11.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 11.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 11.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 11.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 11.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 11.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 11.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

12. Middle East and Africa Muscle Wasting Disorders Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
  • 12.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
  • 12.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
  • 12.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 12.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 12.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 12.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 12.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
        • 12.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
        • 12.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

13. Company Profile

  • 13.1. Biogen, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. F. Hoffmann-La Roche Ltd
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Novartis AG
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Ionis Pharmaceuticals, Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Sarepta Therapeutics, Inc.
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. PTC Therapeutics, Inc.
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Teva Pharmaceutical Industries Ltd.
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Other Notable Players
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 2 Global Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 3 Global Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 4 Global Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 5 Global Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 6 Global Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 7 North America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 8 North America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 9 North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 10 North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 11 North America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 12 North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 13 U.S. Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 14 U.S. Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 15 U.S. Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 16 U.S. Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 17 U.S. Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 18 U.S. Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 19 Canada Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 20 Canada Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 21 Canada Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 22 Canada Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 23 Canada Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 24 Canada Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 25 Rest of North America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 26 Rest of North America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 27 Rest of North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 28 Rest of North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 29 Rest of North America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 30 Rest of North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 31 UK and European Union Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 32 UK and European Union Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 33 UK and European Union Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 34 UK and European Union Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 35 UK and European Union Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 36 UK and European Union Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 37 UK Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 38 UK Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 39 UK Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 40 UK Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 41 UK Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 42 UK Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 43 Germany Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 44 Germany Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 45 Germany Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 46 Germany Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 47 Germany Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 48 Germany Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 49 Spain Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 50 Spain Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 51 Spain Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 52 Spain Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 53 Spain Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 54 Spain Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 55 Italy Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 56 Italy Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 57 Italy Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 58 Italy Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 59 Italy Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 60 Italy Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 61 France Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 62 France Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 63 France Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 64 France Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 65 France Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 66 France Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 67 Rest of Europe Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 68 Rest of Europe Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 69 Rest of Europe Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 70 Rest of Europe Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 71 Rest of Europe Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 72 Rest of Europe Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 73 Asia Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 74 Asia Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 75 Asia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 76 Asia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 77 Asia Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 78 Asia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 79 China Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 80 China Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 81 China Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 82 China Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 83 China Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 84 China Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 85 Japan Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 86 Japan Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 87 Japan Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 88 Japan Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 89 Japan Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 90 Japan Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 91 India Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 92 India Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 93 India Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 94 India Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 95 India Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 96 India Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 97 Australia Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 98 Australia Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 99 Australia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 100 Australia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 101 Australia Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 102 Australia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 103 South Korea Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 104 South Korea Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 105 South Korea Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 106 South Korea Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 107 South Korea Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 108 South Korea Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 109 Latin America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 110 Latin America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 111 Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 112 Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 113 Latin America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 114 Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 115 Brazil Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 116 Brazil Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 117 Brazil Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 118 Brazil Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 119 Brazil Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 120 Brazil Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 121 Mexico Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 122 Mexico Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 123 Mexico Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 124 Mexico Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 125 Mexico Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 126 Mexico Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 127 Rest of Latin America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 128 Rest of Latin America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 129 Rest of Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 130 Rest of Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 131 Rest of Latin America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 132 Rest of Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 133 Middle East and Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 134 Middle East and Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 135 Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 136 Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 137 Middle East and Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 138 Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 139 GCC Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 140 GCC Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 141 GCC Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 142 GCC Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 143 GCC Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 144 GCC Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 145 Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 146 Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 147 Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 148 Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 149 Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 150 Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

  • TABLE 151 Rest of Middle East and Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
  • TABLE 152 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 153 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 154 Rest of Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

  • TABLE 155 Rest of Middle East and Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 156 Rest of Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Muscle Wasting Disorders Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Muscle Wasting Disorders Market: Quality Assurance
  • FIG. 5 Global Muscle Wasting Disorders Market, By Type, 2023
  • FIG. 6 Global Muscle Wasting Disorders Market, By Treatment Type, 2023
  • FIG. 7 Global Muscle Wasting Disorders Market, By End-User, 2023
  • FIG. 8 Global Muscle Wasting Disorders Market, By Geography, 2023
  • FIG. 9 Market Geographical Opportunity Matrix - Global Muscle Wasting Disorders Market, 2023

FIG. 10Market Positioning of Key Muscle Wasting Disorders Market Players, 2023

FIG. 11Global Muscle Wasting Disorders Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 12 Global Muscle Wasting Disorders Market, By Type, 2023 Vs 2032, %
  • FIG. 13 Global Muscle Wasting Disorders Market, By Treatment Type, 2023 Vs 2032, %
  • FIG. 14 Global Muscle Wasting Disorders Market, By End-User, 2023 Vs 2032, %
  • FIG. 15 U.S. Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 16 Canada Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 17 Rest of North America Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 18 UK Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 19 Germany Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 20 Spain Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 21 Italy Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 22 France Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 23 Rest of Europe Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 24 China Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 25 Japan Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 26 India Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 27 Australia Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 28 South Korea Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 29 Rest of Asia Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 30 Brazil Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 31 Mexico Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 32 Rest of Latin America Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 33 GCC Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 34 Africa Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
  • FIG. 35 Rest of Middle East and Africa Muscle Wasting Disorders Market (US$ Million), 2022 - 2032